Navigation Links
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Date:10/21/2008

ROCKVILLE, Md., Oct. 20 /PRNewswire/ -- Glycotex, Inc. today announced enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area.

A previous Phase II Pilot Study, investigating clinical outcomes and safety parameters of GLYC-101 at two doses compared to placebo was completed in April 2008.

The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients will be randomized to receive either GLYC-101 0.1% or GLYC-101 1.0% gel on one lower eyelid, and placebo on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter. The primary efficacy endpoint of the study is time to wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study will observe the effects of the topical agent over the course of one month following the initial treatment with the investigational compound and placebo.

About GLYC-101

GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate is a topical gel to be applied directly on the wound surface. In May 2006, Glycotex completed a Phase II clinical trial of GLYC-101 in Australia, in which GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101.

The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.

About Glycotex, Inc.

Glycotex, Inc
'/>"/>

SOURCE Glycotex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. PURE Bioscience Reports Fourth Quarter and Year End Results
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008
5. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
6. Neptune Technologies & Bioressources Inc. reports first quarter results
7. CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...tCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:...ced updated results from a Phase II study of intra...tatic to the lung in a poster presentation at the ...ting held in Miami Beach, Florida, from November 5...ase II Study of Intravenous REOLYSIN (Wild-type Re...
(Date:11/5/2009)...swire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) ...d quarter ended September 30, 2009. GenVec reporte... the three months ended September 30, 2009 compare...in the comparable quarter of 2008. For the nine mo...as $14.1 million ($0.15 per share), compared to a ...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasd...ucts for processing and storing adult stem cells, ...scal 2010. ,, For the quarter ended September 3...lion, a 15 percent increase over revenues of $4.5 ...ny said the key contributors to the growth in reve...
(Date:11/5/2009)...swire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today... the following investor conferences, and invited i... Credit Suisse Healthcare Conference, Phoeni... at 10 a.m. Mountain Time, NASDAQ... Tuesday, 1 December, 2009 at 10.45 a.m....
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2
...,s Lawrence Berkeley National Laboratory and the U...he world,s first all-integrated sensor circuit bas... electronics made of different crystalline materia... such devices with high uniformity. , Nanostruct...other properties have a number of advantages over ...
.... (Nasdaq: CADX ), a biopharmaceutical company fo...ng proprietary product candidates principally,for ...the company,s,President and CEO Theodore Schroeder...the following investment conferences:, -- Bank o...nce at the Southampton Inn, Long Island, New Y...
...% from Same Prior Year Period, DUBLIN, Calif., Au...tical company dedicated to the discovery, rapid,de...olid tumors and,hematological malignancies, today ... and six months ended June 30, 2008., Total reven... compared,with $4.6 million for the same prior yea...
Other Biology Technology:A first in integrated nanowire sensor circuitry 2A first in integrated nanowire sensor circuitry 3A first in integrated nanowire sensor circuitry 4Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008 2SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:11/4/2009)...fic corridors in the cities of Long Beach and Rive... of preventable childhood asthma, and the true imp...ease has likely been underestimated, according to ...ia (USC). , The study, which appears in an onli...th , estimated that nine percent of all childhood ...
(Date:11/4/2009)... BC - Lowly bacteria, it turns out, hold the power...ants around the world clean up toxic waste on test...cally RDX, were invented back in World War II and ... These high-energy compounds are often used to pro...on of TNT. , But with increased knowledge of t...
(Date:11/4/2009)...sity of Oklahoma at Norman has received more than ...gencies as part of the federal stimulus program, b...ed by OU researchers to $23 million. Thirty-three...nging from archaeology to weather. , "The univer...oach to matching areasof scholarly excellence to f...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Former Associates File Suit Against Univera 3A Dietary Supplement Company Accused of Intimidation Bullying and Unfair Trade Practices 50104 1Former Associates File Suit Against Univera 3A Dietary Supplement Company Accused of Intimidation Bullying and Unfair Trade Practices 50104 2Cell Protein Could Help Spur Malignancy 50101 1Cell Protein Could Help Spur Malignancy 50101 2Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 1Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 2Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 3Partnership for Prescription Assistance Prepared to Help South Dakota Workers Hurt by Recession 50098 4
...OLIS / ST. PAUL (Jan. 8, 2008) Adolescent girls w... less likely to use diet pills, laxatives, or othe...ars later, according to research led by Dianne Neu...tor of Project Eating Among Teens (Project EAT) at...th. , Neumark-Sztainer and Project EAT colleagues...
...lphia, PA, January 8, 2008 Schizophrenia is a dev... contributing to increased risk. Available antips...schizophrenia, but are typically effective in only...cult to predict the effectiveness of a specific dr...hn H. Krystal, M.D., Editor of Biological Psychiat...
...ter Joins Olive, Edwards & Cooper with Technical, ...ound, WASHINGTON, Jan. 7 Today, Olive, Edwards &...ter as a principal who will,provide clients with s...meland security marketplace. His immediate focus w...dgeable about the SAFETY Act (the Support,Anti-Ter...
Other Biology News:U of M research finds disordered eating less common among teen girls who regularly eat family meals 2Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2Chemist Brings SAFETY Act Expertise to Homeland Security Firm 2
Wellpro 384 from Thermo Scientific
Clamps from Thermo Scientific
Scotch-Brite pads from Thermo Scientific
Multidrop DW (Deep Well) (220-240 V) from Thermo Scientific
Biology Products: